Otoprotective and antioxidant activity of cytoflavin in pulmonary tuberculosis patients receiving amikacin

The objective: to study the potential otoprotective and antioxidant activity of cytoflavin in new pulmonary tuberculosis patients receiving aminoglycoside amikacin.

Subjects and Methods. A randomized controlled trial was conducted and included 90 patients with new infiltrative pulmonary tuberculosis with decay, of both genders aged from 20 to 50 years old. Clinical, paraclinical and statistical methods were used in the study. Audiometric screening was carried out by Diagnostic Audiometer AD 226. The degree of antioxidant protection was determined by the oxidation reaction of ABTS in blood serum and plasma.

Results. The study included 4 groups of tuberculosis patients and 1 group of healthy donors. Dissemination of pulmonary tuberculosis in 4 groups was approximately the same and was measured by scores. Prior to the start of treatment in all 4 groups (the group receiving standard chemotherapy (CTX) without amikacin, the group receiving «CTX+amikacin», the group receiving «CTX+cytofl avin», the group receiving «CTX+amikacin+cytofl avin») there was a decrease in blood antioxidant activity compared to Control Group. After 3 months of tuberculosis treatment in all 4 groups, the results improved, while in «CTX+Cytofl avin» Group they were similar to Control Group, and «CTX+Amikacin+Cytofl avin Group», they were only 4.8% less. The elevated level of leukocytes decreased by 10.6% in CTX Group, 16.9% in «CTX+Amikacin» Group, 38.3% in «CTX+Cytofl avin» Group, and 72.3% in «CTX+Amikacin+Cytofl avin» Group. In the study, manifestations of oto- and vestibulotoxicity were found only in the «CTX+Amikacin» Group (in 4/20 (5%)). There were no such cases in «Amikacin+Cytofl avin» Group consisting of 23 patients.

1. Vidal. Spravochnik lekarstvennykh sredstv. [Vidal Compendium of Medicinal Products]. Electronic Compendium. Available at: https://www.vidal.ru/drugs/cytoflavin__9056

2. Darenskaya M.A., Kolesnikova L.I., Kolesnikov S.I. Free radical reactions in socially significant infectious diseases: HIV infection, hepatitis, tuberculosis. Vestnik RAMN, 2020, vol. 75, no. 3, pp. 196–203. (In Russ.)

3. Ekusheva E., Voytenkov V.B., Rizakhanov O.A.The effectiveness of cytoflavin in comprehensive therapy of patients with COVID-19. Journal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2021, vol. 121, no. 12, pp. 33–39. (In Russ.)

4. Kunelskaya N.L., Levina Yu.V., Yanyushkina E.S., Ogorodnikov D.S., Larionova E.V. Possibility of application Mexidol for the treatment of patients suffering from sensorineural hearing loss and cerebrovascular insufficiency. Vestnik Otorinolaringologii, 2019, vol. 84, no. 6, pp. 108–111. (In Russ.) https://doi.org/10.17116/otorino201984061108

5. Lavrik S.Yu., Domitrak S.V., Shprakh V.V., Kolesova L.V. The role of comprehensive metabolic therapy in neurorehabilitation of children with sensorineural hearing loss. Tikhookeanskiy Meditsinskiy Journal, 2013, no. 4, pp. 95–98. (In Russ.)

6. Nikitina O.A., Darenskaya M.A., Semyonova N.V., Kolesnikova L.I. Antioxidant defense system: regulation of metabolic processes, genetic determinants, methods of determination. Sibirsky Nauchny Meditsinsky Journal, 2022, vol. 42, no. 3, pp. 4–17. (In Russ.) https://doi.org/10.18699/SSMJ20220301

7. Solokha A.A., Stavitskaya N.V., Schwartz Y.Sh., Sklyuev S.V., Tursunova N.V. Current methods of prevention of aminoglycoside ototoxicity in patients with pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 3, pp. 87–93. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-3-87-93

8. Shubnikova E.V., Velts N.Yu. Ototoxicity of aminoglycosides, the modern concepts. Antibiotiki i Khimioterapiya, 2022, vol. 67, no. 11–12, pp. 79–90. (In Russ.) https://doi.org/10.37489/0235-2990-2022-67-11-12-79-90

9. Butov D.O., Kuzhko M.M., Kalmykova I.M., Kuznetsova I.M., Butova T.S., Kalmykova I.M. Dynamics of oxidant-antioxidant system in patients with multi drug resistant tuberculosis receiving anti-mycobacterial therapy. J. Pulm. Respir. Med., 2013, no. 3, pp. 161.

10. Dalvi S.M, Patil V.W., Ramraje N.N., Phadtare J.M., Gujarathi S.U. Nitric oxide, carbonyl protein, lipid peroxidation and correlation between antioxidant vitamins in different categories of pulmonary and extra pulmonary tuberculosis. Malays J. Med. Sci., 2013, no. 20, pp. 21–30.

11. Fraser A., Paul M., Attamna A., Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple‐drug‐resistant pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2006.

12. Golubovic S., Stankovic I., Ristic L., Cosic V., Dordevic I., Radovic M. Antioxidant enzymes and l lipid peroxidation products in patients with pulmonary tuberculosis. Med. Pregl., 2010, no. 63, pp. 450–453.

13. Jospe-Kaufman M., Siomin L., Fridman M. The relationship between the structure and toxicity of aminoglycoside antibiotics. Bioorg. Med. Chem. Lett., 2020, vol. 30, no. 13, pp. 127218.

14. Palanisamy G.S., Kirk N.M., Ackart D.F., Shanley C.A., Orme I.M., Basaraba R.J. Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis. PloS One, 2011, no. 6, pp. 634–641.

15. Parchwani Deepak, Singh S.P., Digisha P. Total antioxidant status and lipid peroxides in patients with pulmonary tuberculosis. Nat. J. Comm. Med., 2011, no. 2, pp. 225–228.